Related Experiment Video
Updated: Jul 10, 2026
Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
Published on: July 8, 2025
Treatment of infantile spasms with sodium valproate followed by benzodiazepines
Narong Auvichayapat1, Sompon Tassniyom, Sutthinee Treerotphon
1Division of Pediatric Neurology, Department of Pediatrics, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand. anaron@kku.ac.th
Insights
Sodium valproate with nitrazepam or clonazepam showed a 45.8% complete cessation rate for infantile spasms. This combination therapy is a viable alternative when other treatments are unavailable or ineffective.
Area of Science:
- Pediatric Neurology
- Epileptology
Background:
- Infantile spasms are a severe epilepsy syndrome in infants.
- Standard treatments like ACTH and vigabatrin have limitations.
Purpose of the Study:
- To evaluate the efficacy of sodium valproate combined with nitrazepam or clonazepam for infantile spasms.
- To assess treatment outcomes including spasm cessation, relapse, and psychomotor development.
Main Methods:
- Retrospective analysis of 24 infantile spasms patients treated between 1994-2003.
- Inclusion criteria: clinical diagnosis, hypsarrhythmic EEG, treatment with sodium valproate +/- benzodiazepines.
- Data collected on demographics, etiology, treatment response, and development.
Main Results:
- A 45.8% complete cessation rate and 45.8% rate of 50% spasm reduction were observed.
- Mean time to cessation was 70 days, with an 18.2% relapse rate.
- 83.3% of patients exhibited delayed psychomotor development.
Conclusions:
- Sodium valproate combined with benzodiazepines, particularly clonazepam, is an effective treatment option.
- This combination is recommended when ACTH or vigabatrin are unavailable, not tolerated, or ineffective.
Objective:
To review the result of the infantile spasms' treatment with sodium valproate followed by nitrazepam or clonazepam.
Study Design:
Descriptive retrospective study.
Setting:
Srinagarind Hospital, Department of Pediatrics, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Material And Method:
Twenty-four infantile spasms admitted between January 1994 and December 2003 were analyzed. The inclusion criteria were the patients with infantile spasms clinically diagnosed by the pediatric neurologist, having hypsarrhythmic pattern EEG, and receiving sodium valproate with or without nitrazepam or clonazepam. The patients who had an uncertain diagnosis, incomplete medical record, or that were incompletely followed up were excluded. Data were collected on sex, age at onset of seizure, type of infantile spasms, associated type of seizure, predisposing etiological factor, neuroimaging study, and the result of treatment including cessation of spasms, subsequent development of other seizure types, quantitative reduction of spasms, relapse rates of spasms, psychomotor development, and adverse effects of AEDs.
Results:
The mean age at onset was 177 days. The male-to-female ratio was 1:1.2. There were 13 cryptogenic (54.2%) and 11 symptomatic (45.8%) infantile spasms. The most common predisposing etiological factors in symptomatic cases were hypoxic ischemic encephalopathy (45.5%) and microcephaly (36.4%), respectively. Ten patients received sodium valproate (41.7%), another 10 received sodium valproate with clonazepam (41.7%), and four received sodium valproate with nitrazepam (16.7%). Both, the complete cessation rate and the 50% reduction of spasms rate were 45.8%. The duration to complete cessation was 70 days. The relapse rate was 18.2%. The rate of delayed psychomotor development was 83.3%. The mean duration of follow-up was 49.6 months.
Conclusion:
The authors propose to use sodium valproate concomitantly with benzodiazepines, especially clonazepam, in situations such as unavailability, intolerability, or adverse effects of ACTH or vigabatrin, or in a patient who does not respond to ACTH or vigabatrin.
Related Concept Videos
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:08Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:29Spasmolytic Agents: Chemical Classification
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also promote...
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
01:14CNS Depressants: Barbiturates and Benzodiazepines